Besides using adenovirus-mediated overexpression, Cho et al (2011) and Sheng et al (2011) also generated a LCN13 transgenic mouse line characterized by improved glucose handling, insulin responsiveness and ameliorated hepatic steatosis upon HFD treatment (Cho et al, 2011; Sheng et al, 2011). This evidence concerns the gene OBP2A and fatty liver disease.